At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

Discover how in some communities around the world, the prevalence of rare diseases is higher due to factors like cousin ...

Gene therapies have seen a drop in investor interest lately. Despite this, Kriya Therapeutics seems to be attracting funds in ...

Once thought to be under control, yellow fever is making an alarming comeback, and the numbers are climbing. With treatment ...

As the release of a CRL declining Lykos' therapy generates a strong reaction from MAPS, delve into what this new transparency ...

Multichain biotherapeutics continue to be a promising therapeutic modality. “These therapeutic recombinant proteins are typically assembled from at least three distinct polypeptide chains,” says ...

As in July, there were six major merger and acquisition (M&A) deals that were inked during the month of August. Pharma giant AbbVie’s $1.2 billion buyout of American biotech Gilgamesh Pharmaceuticals’ ...

Given the rise of artificial intelligence (AI) in the biotechnology industry in the last few years, it is no surprise that AI specialists represent a career in high demand right now – a trend that ...